Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib vs hydroxyurea in intermediate-2/high-risk myelofibrosis
CTR20202130Phase 3Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of jaktinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Nov 2020; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on CTR20202130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202130.